Oncovita
Blood & Organ Banks · Idaho, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
28 Rue Docteur Roux, Paris, Idaho, 83261...Website
www.oncovita.frRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
2
1
About Oncovita
Oncovita is a biotech company dedicated to the development of life-saving new treatments for unmet medical needs, in particular anti-cancer therapies. Oncovita is a spin-off of Institut Pasteur, founded by Frédéric Tangy, PhD, director of the viral genomics and vaccination unit. He has developed an oncolytic virus platform allowing the company to offer new therapies against multiple types of cancer. At the core of this technology is a modified version of the measles vaccine virus which significantly increases potential to specifically target and reactivates patient immunity against the tumor. This platform, based on one of the safest human viruses, also has a great potential for next-generation products. Oncovita has started regulatory preclinical development for the candidate.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncovita your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Oncovita has new funding data
Earning: See what the market has to say on Oncovita recently announced quarterly report
Check out if Oncovita is spiking on competitors!
Click to see if Oncovita had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Oncovita
Oncovita, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Oncovita has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Oncovita launches new products
Recommended Actions
Find VP level buyers at Oncovita
Find 2 more new buyers
Company Profile Activity
Activity Insights
Oncovita is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Oncovita is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Oncovita.
Oncovita Tech Stack
A closer look at the technologies used by Oncovita
See more technologies
Oncovita News & Media
Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in Budapest
Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in BudapestOncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from itsOncovita appoints Stéphane Altaba as Chief Executive Officer
Paris, France, October 9th, 2024 - Oncovita, a biotechnology company specializing in the development of therapeutic cancer vaccines and prophylactic vaccines, today announced the appointment of Dr. Stéphane Altaba as its new Chief Executive Officer.Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncovita
Sign Up For FreeTo access detailed company insights
Oncovita is a biotech company dedicated to the development of life-saving new treatments for unmet medical needs, in particular anti-cancer therapies. Oncovita is a spin-off of Institut Pasteur, founded by Frédéric Tangy, PhD, director of the viral genomics and vaccination unit. He has developed an oncolytic virus platform allowing the company to o... Read More
